# A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.

> **NCT07283367** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 502 (estimated)

## Conditions studied

- CRC

## Interventions

- **DRUG:** Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin
- **DRUG:** Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin
- **DRUG:** Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine

## Key facts

- **NCT ID:** NCT07283367
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-22
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 502 (ESTIMATED)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07283367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07283367, "A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07283367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*